Natural killer (NK) cells contribute to early antiviral immunity, and in this preprint, Maucourant et al. report reduced NK cell counts in the peripheral blood of 27 patients hospitalized with moderate or severe COVID-19. In early COVID-19, NK cell activation across distinct subsets was elevated in peripheral blood, mirroring the activation signature of NK cells in the bronchoalveolar lavage fluid of patients with COVID-19. Interestingly, severe hyperinflammation was associated with the proliferation and activation of ‘adaptive’ NK cells, a specialised sub-population with enhanced antibody-dependent cellular cytotoxicity, as well as the arming of CD56bright NK cells with cytotoxic molecules. These results suggest that a distinct NK cell immunophenotype is associated with the severity of COVID-19. Further studies are necessary to define the protective antiviral versus the detrimental pathological roles of NK cells in patients with COVID-19.
Change history
15 February 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41577-020-00419-5
References
Original article
Maucourant, C. et al. Natural killer cell activation related to clinical outcome of COVID-19. Preprint at medRxiv https://www.medrxiv.org/content/10.1101/2020.07.07.20148478v1 (2020)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Alrubayyi, A. NK cells in COVID-19: protectors or opponents?. Nat Rev Immunol 20, 520 (2020). https://doi.org/10.1038/s41577-020-0408-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-0408-0
This article is cited by
-
Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells
Inflammopharmacology (2023)
-
Systemic and organ-specific immune-related manifestations of COVID-19
Nature Reviews Rheumatology (2021)